ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
- 2 January 2021
- journal article
- editorial
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (4) , 1906-1907
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort StudyAnnals of Surgical Oncology, 2021
- Chyle Leak Following Radical En Bloc Esophagectomy with Two-Field Nodal Dissection: Predisposing Factors, Management, and OutcomesAnnals of Surgical Oncology, 2020
- Neoadjuvant Treatment for Patients With Localized Pancreatic AdenocarcinomaJAMA Oncology, 2020
- Impact of Neoadjuvant Systemic Therapy on Pancreatic Fistula Rates Following Pancreatectomy: a Population-Based Propensity-Matched AnalysisJournal of Gastrointestinal Surgery, 2020
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerNew England Journal of Medicine, 2018
- Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic CancerAnnals of Surgery, 2014